EHA / 13th Congress / Program overview per day / Sunday Program
Sunday Program
Simultaneous Sessions | Science in progress | Clinical Trial Update | Hematology-in-focus Session | Plenary Session 2 |
SIMULTANEOUS SESSIONS
08:00 – 09:15, Auditorium 1
CHRONIC MYELOID LEUKEMIA – CLINICAL II
Chairs: A Petzer (Krankenhaus der Barmherzigen Schwestern, Linz, Austria)
S Soverini (Institute of Hematology "Seràgnoli", Bologna, Italy)
08:00 – 08:15
0881 EFFICACY OF DASATINIB IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE (CML-CP)
J. Cortes, G. Borthakur, D.M. Jones, S. O’Brien, C.A. Koller, C. Nicaise,
G. Garcia-Manero, A. Ferrajoli, H.M. Kantarjian (MD Anderson Cancer
Center, Houston, United States of America)
08:15 – 08:30
0882 MARKED TELOMERE EROSION OF PH-NEGATIVE MYELOID CELLS AFTER SUCCESSFUL TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA INDICATES SEVERE PROLIFERATIVE STRESS AND POTENTIAL PERMANENT DAMAGE OF HEMATOPOIESIS
M. Ladetto, C. Lobetti Bodoni, E. Genuardi, M. Genuardi, V. Giai, A. Rocci,
L. Monitillo, D. Drandi, A. Risso, B. Mantoan, S. Ferrero, R. Critelli,
C. Tarella, M. Boccadoro, D. Ferrero (Università di Torino, Torino, Italy)
08:30 – 08:45
0883 NILOTINIB IN CHRONIC MYELOGENOUS LEUKAEMIA IN CHRONIC PHASE (CML-CP) PATIENTS WITH IMATINIBRESISTANCE OR -INTOLERANCE: UPDATED PHASE 2 RESULTS
H.M. Kantarjian, F.J. Giles, K.N. Bhalla, R.A. Larson, N. Gatterman,
O.G. Ottmann, A. Haque, N. Gallagher, M. Baccarani, P.H. Le Coutre
(M.D. Anderson Cancer Center, Houston, USA)
08:45 – 09:00
0884 DOSE FINDING STUDY OF IMATINIB IN COMBINATION WITH INTRAVENOUS CYTARABINE: FEASIBILITY AND EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA
W. Deenik, B. van der Holt, G.E.G. Verhoef, W.M. Smit, M.J. Kersten,
J.C. Kluin-Nelemans, L.F. Verdonck, A. Ferrant, A.V.M.B. Schattenberg,
J.J.W.M. Janssen, P. Sonneveld, M. van Marwijk Kooy, S. Wittebol,
R. Willemze, P.W. Wijermans, P.H.M. Westveer, H.B. Beverloo, P. Valk,
B. Löwenberg, G.J. Ossenkoppele, J.J. Cornelissen (Erasmus
University Medical Center, Rotterdam, The Netherlands)
09:00 – 09:15
0933 DASATINIB EFFICACY AFTER IMATINIB FAILURE BY DOSING SCHEDULE AND BASELINE BCR-ABL MUTATION STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
A. Hochhaus, M.C. Müller, J. Cortes, D.W. Kim, Y. Matloub,
L. Ploughman, T. Hughes (Medizinische Klinik, Medizinische Fakultät
Mannheim der Universität Heidelberg, Mannheim, Germany)
SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall A3
STEM CELL TRANSPLANTATION I
Chairs: P Ljungman (University Hospital, Huddinge, Sweden)
A Urbano Ispizua (Hospital Universitario Virgen del Rocio,
Barcelona, Spain)
08:00 – 08:15
0885 HAPLO-SCT WITH TK+ LYMPHOCYTES PRODUCE LEUKEMIA FREE SURVIVAL COMPARABLE TO UNRELATED BONE MARROW AND CORD BLOOD TRANSPLANTATION IN HIGH RISK ACUTE LEUKEMIA: "TK007" PHASE II STUDY FINAL ANALYSIS
M.T. Lupo Stanghellini, F. Ciceri, C. Bonini, A. Bondanza, C. Traversari,
M. Salomoni, L. Turchetto, S. Colombi, M. Bernardi, J. Peccatori,
A. Pescarollo, P. Servida, Z. Magnani, S.K. Perna, V. Valtolina, F. Crippa,
L. Callegaro, E. Spoldi, R. Crocchiolo, K. Fleischhauer, M. Ponzoni,
L. Vago, A. Santoro, E. Todisco, J. Apperley, S. Slavin, E.M. Weissinger,
B. Hertenstein, M. Bregni, C. Gallo Stampino, P. Bruzzi, C. Bordignon
(San Raffaele Scientific Institute, IRCCS, Milan, Italy)
08:15 – 08:30
0886 HLA-DP AS SPECIFIC TARGET FOR GRAFT VERSUS LEUKEMIA REACTIVITY IN HLA-CLASS II EXPRESSING HEMATOLOGICAL MALIGNANCIES
C.E. Rutten, S.A.P. van Luxemburg-Heijs, M. Griffioen, W.A.F. Marijt,
I. Jedema, M.H.M. Heemskerk, F.M. Posthuma, R. Willemze,
J.H. Falkenburg (Leiden University Medical Center, Leiden,
The Netherlands)
08:30 – 08:45
0887 G TO C TRANSITION AT POSITION -173 OF MIF GENE OF THE RECIPIENT IS ASSOCIATED WITH IMPROVED OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
G.C. Hildebrandt, Y.Y. Chang, H.T. Greinix, A.M. Dickinson, D. Wolff,
G.H. Jackson, R. Andreesen, E. Holler (University of Regensburg
Medical Center, Regensburg, Germany)
08:45 – 09:00
0888 BONE MARROW TRANSPLANTATION IN PATIENTS WITH HOMOZYGOUS THALASSEMIA
S. Santarone, E. Di Bartolomeo, P. Bavaro, P. Olioso, G. Papalinetti,
P. Di Carlo, A. Angelone, M. Di Nicola, P. Di Bartolomeo (Bone Marrow
Transplant Center, Pescara, Italy)
09:00 – 09:15
0889 MONITORING OF VIRUS-SPECIFIC IMMUNE RECONSTITUTION IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
S. Borchers, S. Luther, B. Grabow, A. Ganser, E.M. Weissinger
(Hannover Medical School, Hannover, Germany)
SIMULTANEOUS SESSIONS
08:00 - 09:15, Auditorium 2
ACUTE MYELOID LEUKEMIA – CLINICAL
Chairs: H Dombret (Hôpital Saint-Louis, Paris, France)
B Gibson (UK Childhood Leukaemia Working Party, Glasgow,
United Kingdom)
08:00 – 08:15
0890 AMONAFIDE: A TOPOISOMERASE II INHIBITOR WITH NOVEL PHARMACOLOGICAL PROPERTIES AND UNIQUE ACTIVITY FOR THE TREATMENT OF SECONDARY AML
R.L. Capizzi, A.S.L. Lundberg, M.C. Chau, D.J.F. Fernandes,
A.M.A. Ajami (Xanthus Pharmaceuticals, Inc., Cambridge, USA)
08:15 – 08:30
0891 PATIENT AND DONOR CHARACTERISTICS DETERMINE OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA
C. Craddock, S. Tauro, L. Buckley, P. Kottaridis, E. Thelouli,
K. Thomson, D. Milligan, E. Liakopoulou, J. Snowden, J. Marsh,
A. Hunter, J. Yin, A. Peniket, M. Cook, S. Mackinnon, N. Russell
(Centre for Clinical Haematology, Birmingham, United Kingdom)
08:30 – 08:45
0892 PHASE II STUDY OF SINGLE AGENT CLOFARABINE IN PREVIOUSLY UNTREATED OLDER ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) UNLIKELY TO BENEFIT FROM STANDARD INDUCTION CHEMOTHERAPY
H. Erba, H. Kantarjian, D. Claxton, M. Arellano, R. Lyons,
T. Kovacsovics, J. Gabrilove, S. Eckert, R. Abichandani, S. Faderl
(University of Michigan Comprehensive Cancer Center, Ann Arbor, USA)
08:45 – 09:00
0893 PATIENT-REPORTED OUTCOMES IN LEUKEMIA RANDOMIZED CONTROLLED TRIALS. A SYSTEMATIC REVIEW TO EVALUATE THE ADDED VALUE IN SUPPORTING CLINICAL DECISION-MAKING
F. Efficace, G. Kemmler, M. Vignetti, F. Mandelli, S. Molica, B. Holzner
(GIMEMA, Rome, Italy)
09:00 – 09:15
0894 A CLINICAL AND IMMUNOLOGICAL PHASE II TRIAL OF WILMS TUMOR GENE PRODUCT 1 (WT1) PEPTIDE VACCINATION IN PATIENTS WITH AML AND MDS
A.L. Letsch, U. Keilholz, A.M. Asemissen, A. Busse, S. Bauer,
I.W. Blau, W.K. Hofmann, L. Uharek, E. Thiel, C. Scheibenbogen
(Hematology and Oncology, Berlin, Germany)
SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C1
NON-HODGKIN'S LYMPHOMA – BIOLOGY
Chairs: J Fitzgibbon (Queen Mary School of Medicine and Dentistry,
London, United Kingdom)
G Gaidano (Amedeo Avogadro University of Eastern Piedmont,
Novara, Italy)
08:00 – 08:15
0895 RBL2/P130 NETWORK ABNORMALITIES IN ENDEMIC BURKITT’S LYMPHOMA EXPLORED BY GENE EXPRESSION ANALYSIS
P.P. Piccaluga, G. De Falco, E. Leucci, W. Mwanda, L. Leoncini,
S.A. Pileri (Section of Hematopathology, Bologna, Italy)
08:15 – 08:30
0896 GENOME-WIDE ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION OF HIV-RELATED NON-HODGKIN LYMPHOMA: IDENTIFICATION OF RECURRENT GENETIC LESIONS SPECIFICALLY ASSOCIATED WITH THE DISEASE
D. Capello (University of Eastern Piedmont, Novara, Italy)
08:30 – 08:45
0897 TP53 MUTATION IDENTIFIES A HIGH RISK GROUP OF PATIENTS AT DIAGNOSIS OF FOLLICULAR LYMPHOMA AND IS ASSOCIATED WITH SHORTER TIME TO DISEASE PROGRESSION AND OVERALL SURVIVAL
D. O'Shea, C. O'Riain, C. Taylor, R. Waters, E. Carlotti, F. MacDougall,
J. Gribben, A. Rosenwald, L. Rimsza, E.B. Smeland, N. Johnson,
E. Campo, W.C. Chan, R.D. Gascoyne, L.M. Staudt, T.A. Lister,
J. Fitzgibbon (Centre for Medical Oncology, London, United Kingdom)
08:45 – 09:00
0898 BCL-2/IGH PCR VALUES AT THE END OF INDUCTION TREATMENT ARE NOT PREDICTIVE FOR PROGRESSION FREE SURVIVAL IN RELAPSED/RESISTANT FOLLICULAR LYMPHOMA: RESULTS OF A PROSPECTIVE RANDOMIZED PHASE III INTERGROUP TRIAL
M.H.J. van Oers, B.A. van der Reijden, E. Tönnissen, M. van Glabbeke,
L. Giurgia, R. Klasa, R.E. Marcus, M. Wolf, E. Kimby, M. van ‘t Veer,
A. Vranovsky, H. Holte, A. Hagenbeek (Academic Medical Center,
Amsterdam, The Netherlands)
09:00 – 09:15
0899 REAL-TIME QUANTITATIVE PCR ANALYSIS FOR BCL2/IGH IN THE PHASE III FIRST-LINE INDOLENT TRIAL OF 90Y-IBRITUMOMAB TIUXETAN AS CONSOLIDATION OF FIRST REMISSION IN ADVANCED-STAGE FOLLICULAR LYMPHOMA
L. Goff, K. Summers, S. Iqbal, J. Kuhlman, M. Kunz, T. Louton,
A. Hagenbeek, T. Lister, A. Rohatiner (CR-UK Medical Oncology Unit,
London, United Kingdom)
SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C2
HEMOGLOBINOPATHIES AND PAROXYSMAL NOCTURNALHEMOGLOBINURIA
Chairs: R Galanello (Ospedale Microcitemico, Cagliara, Italy)
M Layton (Imperial College, London, United Kingdom)
08:00 – 08:15
0900 SERUM DICKKOPF-1 IS INCREASED AND CORRELATES WITH BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIAINDUCED OSTEOPOROSIS. REDUCTION POST ZOLEDRONIC ACID ADMINISTRATION
E. Voskaridou, D. Christoulas, C. Xirakia, K. Varvagiannis,
G. Boutsikas, E. Terpos (Thalassemia Center, Laikon General Hospital,
Athens, Greece)
08:15 – 08:30
0901 COMPARISON OF DEFERASIROX, DEFERIPRONE, AND DESFERRIOXAMINE EFFECTIVENESS ON MYOCARDIAL IRON CONCENTRATIONS AND BIVENTRICULAR FUNCTION BY QUANTITATIVE MR IN BETA-THALASSEMIA MAJOR
A. Pepe, A. Ramazzotti, P. Cianciulli, A. Spasiano, M. Capra,
C. Borgna-Pignatti, M.C. Putti, A. Lippi, M.A. Romeo, M.G. Bisconte,
A. Filosa, V. Caruso, A. Quarta, L. Pitrolo, V. De Sanctis, C. Gerardi,
A. Maggio, A. Pietrangelo, G. Rossi, M. Lombardi (Institute of Clinical
Physiology, CNR, Pisa, Italy)
08:30 – 08:45
0902 A HOMOZYGOUS DELETION OF THE MAJOR ALPHA GLOBIN REGULATORY ELEMENT (HS-40) RESPONSIBLE FOR A SEVERE CASE OF HEMOGLOBIN H DISEASE
M.C. Sollaino, M.E. Paglietti, D. Loi, R. Congiu, R. Podda, R. Galanello
(Ospedale Regionale Microcitemie, Cagliari, Italy)
08:45 – 09:00
0903 IMPROVEMENT IN FATIGUE WITH ECULIZUMAB TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) OCCURS INDEPENDENT OF CHANGES IN ANEMIA
A. Hill, P. Muus, U. Dührsen, G. Socié, A. Risitano, R. De Paz,
E. Van den Neste, A. Zanella, J.S. Lai, P. Hillmen, R. Rother, D. Cella
(Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom)
09:00 – 09:15
0904 MODULATION IN HEMODYNAMIC AND ADHERENCE OF SICKLED RED BLOOD CELLS ON ENDOTHELIAL CELLS TREATED BY HYDROXYUREA
E. Verger, S. Laurance, A. Bruel, D. Schoëvaërt, M.H. Odièvre,
O. Fenneteau, C. Claudine, J. Elion (INSERM, Paris, France)
SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C3
MYELODYSPLASTIC SYNDROMES
Chairs: J Boultwood (University of Oxford, Oxford, United Kingdom)
A Kuendgen (University of Düsseldorf, Düsseldorf, Germany)
08:00 – 08:15
0905 GENOME-WIDE MOLECULAR ALLELOKARYOTYPING USING SNP ARRAY DISCLOSED ASSOCIATION BETWEEN A UNIPARENTAL DISOMY AND HOMOZYGOUS MUTATION IN MYELODYSPLASTIC SYNDROMES
M. Sanada, S. Lee Yung, T. Suzuki, G. Yamamoto, Y. Nannya, M. Sakata,
M. Kato, K. Kumano, N. Kawamata, H. Mori, M. Kurokawa, S. Chiba,
M. Omine, H.P. Koeffler, S. Ogawa (University of Tokyo, Tokyo, Japan)
08:15 – 08:30
0906 PROGNOSTIC IMPACT OF ADDITIONAL CHROMOSOMAL ABERRATIONS TO 5Q- IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES
M. Mallo, J. Cervera, J. Schanz, B. Espinet, E. Such, E. Luño, C. Steidl,
M.L. Martín, U. Germing, I. Granada, M. Pfeilstöcker, J.M. Hernández,
T. Noesslinger, M.J. Calasanz, P. Valent, R. Collado, C. Fonatsch, E. Bureo,
M. Lübbert, R. Ríos, R. Stauder, E. Arranz, B. Hildebrandt, J.C. Cigudosa,
C. Pedro, M. Salido, L. Arenillas, G.F. Sanz, MA. Sanz, A. Valencia,
L. Florensa, D. Haase, F. Solé (Hospital del Mar, Barcelona, Spain)
08:30 – 08:45
0907 CHARACTERISTICS OF DISEASE PROGRESSION IN 3144 PATIENTS WITH MYELODYSPLASTIC SYNDROME
F. Zohren, C. Strupp, A. Kündgen, A. Giagounidis, B. Hildebrandt,
U. Suter, R. Haas, U. Germing (Heinrich-Heine Universität Duesseldorf,
Duesseldorf, Germany)
08:45 – 09:00
0908 AUTOCRINE GDF15 IS NECESSARY FOR NORMAL ERYTHROID DIFFERENTIATION AND ITS OVEREXPRESSION IN RARS PATIENTS CONSTITUTES A POSSIBLE COMPENSATORY MECHANISM FOR INEFFECTIVE ERYTHROPOIESIS
J.M. Ramirez, O. Shaad, S. Durual, D. Cossali, M. Docquier, P. Beris,
P. Descombes, T. Matthes (Hôpital Universitaire de Genève, Genève,
Switzerland)
09:00 – 09:15
0909 IMPACT OF CYTOGENETIC ABNORMALITIES ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR THERAPYRELATED MYELODYSPLASTIC SYNDROME (T-MDS) AND ACUTE MYELOID LEUKEMIA. A REPORT FROM THE MDS SUBCOMMITTEE OF THE CHRONIC LEUKEMIA WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATI
N. Kröger, R. Brand, A. Van Biezen, A. Zander, J. Dierlamm, D. Niederwieser,
A. Devergie, R. Trapani, J. Cornish, P. Van der Borne, P. Ljungman,
A. Gratwohl, C. Cordonnier, D. Beelen, E. Deconinck, A. Symoneidis,
T De Witte (University Hospital Hamburg, Hamburg, Germany)
SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C4
THROMBOSIS
Chairs: To be announced
H Büller (Academic Medical Center, Amsterdam, The Netherlands)
08:00 – 08:15
0910 ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-FIXED-DOSE OF WARFARIN IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH THALIDOMIDE-CONTAINING REGIMENS: A RANDOMIZED, CONTROLLED TRIAL
A. Palumbo, M. Cavo, S. Bringhen, A. Zaccaria, A. Spadano,
S. Palmieri, N. Pescosta, T. Caravita, M. Spriano, C. Cangialosi,
L. Castagna, F. Morabito, R. Ria, E. Zamagni, P. Tacchetti,
G. Benevolo, M. Aragno, V. De Stefano, F. Elice, M. Boccadoro
(A.O.U. San Giovanni Battista, Torino, Italy)
08:15 – 08:30
0911 SYNERGISTIC EFFECTS OF HYPOFIBRINOLYSIS AND GENETIC AND ACQUIRED RISK FACTORS IN VENOUS THROMBOSIS
M.E. Meltzer, T. Lisman, C.J.M. Doggen, P. De Groot, F. Rosendaal
(University Medical Center Utrecht/Leiden University Medical Center,
Utrecht / Leiden, The Netherlands)
08:30 – 08:45
0912 ARSENIC TRIOXIDE (AS2O3) MODULATES THE PROCOAGULANT ACTIVITIES OF FRESHLY ISOLATED ACUTE PROMYELOCYTIC LEUKEMIA (APL) BLASTS: A COMPARISON WITH ALL-TRANS RETINOIC ACID (ATRA)
D. Balducci, M. Marchetti, L. Russo, A. Vignoli, I. Previtali, T. Barbui,
A Rambaldi, A Falanga (Ospedali Riuniti, Bergamo, Italy)
08:45 – 09:00
0913 THROMBOPHILIC ALTERATIONS AND RISK OF VENOUS THROMBOEMBOLISM IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE AND HIGH-DOSE DEXAMETHASONE
E. Zamagni L. Valdrè, M. Cini, C. Legnani, P. Tosi, P. Tacchetti, M. Ceccolini,
F. Patriarca, L. Catalano, A.F. Casulli, S. Volpe, G. Perrone, L. Masini,
A. Ledda, S. Falcioni, A. Brioli, A. Gozzetti, C. Califano, M.C. Pallotti,
C. Cellini, L. Pantani, A. Petrucci, A. Carubelli, M. Baccarani, G. Palareti,
M. Cavo (Istituto di Ematologia Seragnoli, Bologna, Italy)
09:00 – 09:15
0914 ABSENCE OF RESIDUAL VEIN THROMBOSIS AFTER AN EPISODE OF IDIOPATHIC DEEP VEIN THROMBOSIS: SHORT-TERM ANTICOAGULATION IS SAFE. THE “EXTENDED DACUS STUDY”
S. Siragusa (University Hospital of Palermo, Palermo, Italy)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall A2
MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES – CLINICAL
Chairs: P Moreau (University Hospital Hôtel-Dieu, Nantes, France)
U-H Mellqvist (Sahlgrenska, Gothenburg, Sweden)
10:30 – 10:45
0915 MELPHALAN 200 MG/M2 (MEL200) VERSUS MELPHALAN 100MG/M2 (MEL100) IN NEWLY DIAGNOSED MYELOMA PATIENTS:A PROSPECTIVE, RANDOMIZED PHASE III STUDY
M. Boccadoro, S. Bringhen, M.T. Petrucci, A. Falcone, A.M. Liberati,
S. Morandi, A. Gabbas, A. Capaldi, V. Callea, V. De Stefano,
V. Bongarzoni, M. Rizzo, E. Calabrese, F. Cavallo, F. Gay, P. Omedè,
P. Musto, R. Foà, A. Palumbo (A.O.U. San Giovanni Battista, Torino,
Italy)
10:45 – 11:00
0916 ORAL MELPHALAN, PREDNISONE AND THALIDOMIDE INELDERLY MULTIPLE MYELOMA PATIENTS: UPDATED RESULTSOF A RANDOMIZED CONTROLLED TRIAL
A. Palumbo, S. Bringhen, A.M. Liberati, T. Caravita, A. Falcone,
V. Callea, C. Cangialosi, M. Grasso, M. Galli, F. Rossini, L. Catalano,
V. De Stefano, S. Morandi, M.T. Petrucci, P. Falco, A. Larocca,
V. Magarotto, G. Ciccone, M. Cavo, M. Boccadoro (A.O.U. San
Giovanni Battista, Torino, Italy)
11:00 – 11:15
0917 A NOVEL STAGING SYSTEM FOR LIGHT CHAIN AMYLOIDOSISINCORPORATING FREE LIGHT CHAIN LEVELS
K. Kumar, A. Dispenzieri, M.Q. Lacy, S.R. Hayman, F.K. Buadi,
S.R. Zeldenrust, N.L. Leung, M.R. Ramirez-Alvarado, R.A. Kyle,
S.V. Rajkumar, M.A. Gertz (Mayo Clinic, Rochester, USA)
11:15 – 11:30
0918 BORTEZOMIB, LOW DOSE INTRAVENOUS MELPHALAN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPL EMYELOMA
R. Popat, H. Oakervee, C. Williams, M. Cook, C. Craddock, S. Basu,
C. Singer, L. Odeh, N. Foot, S. Joel, S. Hallam, S.J. Harding, G. Mead,
J. Cavenagh (St. Bartholomew's Hospital, London, United Kingdom)
11:30 – 11:45
0919 A COMPARISON OF REDUCED-INTENSITY CONDITIONING FOR ALLOGRAFTING (RICT) FOLLOWING AUTOGRAFTING (ASCT) VERSUS DOUBLE AUTOGRAFTING FOR NEWLY MULTIPLE MYELOMA (MM) PATIENTS
A.M. Carella, M. Spriano, G. Catania (Hematology Division, Genoa,
Italy)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Auditorium 1
ACUTE LYMPHOBLASTIC LEUKEMIA – CLINICAL
Chairs: R Pieters (Erasmus Medical Center, Rotterdam, The Netherlands)
J Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)
10:30 – 10:45
0920 TREATMENT OF ADULTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA WITH MULTIPLE DOSES OF INTRAVENOUS PEGYLATED ASPARAGINASE IN AN INTENSIFIED PEDIATRIC REGIMEN
P. Srivastava, K. Watkins, L. Mark, A. Mohrbacher, A.S. Yang,
V. Avramis, D. Douer (USC/Keck School of Medicine, Los Angeles, USA)
10:45 – 11:00
0921 SHORT-COURSE IMATINIB (IM) ADDED TO CHEMOTHERAPY IMPROVES EARLY BUT NOT LONG-TERM OUTCOME IN ADULT PH/BCR-ABL+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): 5-YEAR FOLLOW-UP RESULTS OF STUDY NILG-09
R. Bassan, T. Intermesoli, E. Oldani, G. Rossi, E. Borlenghi,
E.M. Pogliani, E. Terruzzi, P. Fabris, E. Di Bona, G. Gianfaldoni,
C. Romani, A. Cortelezzi, D. Mattei, O. Spinelli, A. Rambaldi (Ospedali
Riuniti, Bergamo, Italy)
11:00 – 11:15
0922 DASATINIB MONOTHERAPY AS 1ST LINE TREATMENT OF PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS: UPDATE OF THE GIMEMA LAL1205 STUDY
R. Foà, P. Fazi, A. Vitale, A. Guarini, M.S. De Propris, L. Elia, G. Cimino,
M. Luppi, C. Castagnola, S. Sica, R. Nieddu, M.-N. Piersantelli,
F. Ferrara, F. Nobile, R. Fanin, G. Martinelli, F. Mandelli, G. Meloni,
M. Baccarani (Division of Hematology, Rome, Italy)
11:15 – 11:30
0923 DASATINIB IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY LEUKEMIA: PRELIMINARY RESULTS OF THE CA180018 PHASE I/II STUDY FROM THE ITCC CONSORTIUM
C.M. Zwaan, P. Kearns, M.L. Den Boerd, H.B. Beverloo,
V.H.J. Van der Velden, J.M.A. Van Tornout, D. Derreumaux,
T. Lehrnbecher, F. Mechinaud, C. Rizzari, A. Baruchel, R. Pieters
(Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands)
11:30 – 11:45
0924 IMPACT OF ALLOGENEIC STEM CELL TRANSPLANTATION (SCT ON MINIMAL RESIDUAL DISEASE (MRD) AND BCR-ABL KINASE DOMAIN MUTATIONS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL)
H. Pfeifer, S. Wystub, B. Wassmann, P. Brück, N. Goekbuget,
L. Wunderle, J. Chromik, H. Serve, D. Hoelzer, O.G. Ottmann
(Universitätsklinik Frankfurt, Frankfurt, Germany)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall A3
MYELODYSPLASTIC SYNDROMES, MYELOPROLIFERATIVE DISORDERS AND CHRONIC MYELOID LEUKEMIA
Chairs: M Cazzola (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)
A Almeida (Instituto Português de Oncologia, Lisbon, Portugal)
10:30 – 10:45
0925 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN NAMED PATIENT PROGRAM
P. Musto, L. Maurillo, A. Spagnoli, A. Gozzini, F. Rivellini, C. Tatarelli,
M. Lunghi, C. Fili, E. Orciuolo, L. Ciuffreda, E. Vigna, P. Della Cioppa,
D. Ferrero, S. Palmieri, G. Palumbo, N. Di Renzo, E. Oliva, G. Sanpaolo,
D. Pastore, A. Tonso, A. Santagostino, O. Villani, F. D'Auria, A. D'Arco,
G. Gaidano, S. Galimberti, D. Russo, A. Venditti, M.A. Aloe-Spiriti,
G. Leone, V. Santini (CROB, Centro di Riferimento Oncologico della
Basilicata, Rionero In Vulture (pz), Italy)
10:45 – 11:00
0926 IMMUNOSUPPRESSION FOR PATIENTS WITH LOW AND INTERMEDIATE RISK MYELODYSPLASTIC SYNDROME: A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL COMPARING ANTITHYMOCYTE GLOBULIN + CYCLOSPORINE WITH BEST SUPPORTIVE CARE: SAKK 33/99
J. Passweg, M. Simcock, A. Giagounidis, C. Aul, C. Dobbelstein,
M. Stadler, G. Ossenkoppele, W. Hofmann, K. Schilling, A. Tichelli,
A. Ganser (Geneva University Hospitals, Geneva, Switzerland)
11:00 – 11:15
0927 IMATINIB DISCONTINUATION AFTER IMATINIB/INTERFERON ALPHA COMBINATION THERAPY IS ASSOCIATED WITH CONTINUOUS RESPONSES IN THE MAJORITY OF PATIENTS
A. Hochhaus, A. Neubauer, M.C. Mueller, S. Napieralski, P. Erben,
T. Bostel, R. Hehlmann, A. Burchert (III.MedicalKlinik, Mannheim,
Germany)
11:15 – 11:30
0928 PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH -7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)
G.J. Mufti, G. Garcia-Manero, N. Hovarth, Z. Lim, B. Quesnel,
G. Leone, J. Bennett, G. Sanz, D. McKenzie, J. Backstrom, C.L. Beach
(Kings College Hospital, London, United Kingdom)
13:30 – 11:45
0929 SOCS2: INHIBITOR OF JAK2V617F-MEDIATED SIGNAL TRANSDUCTION
H. Quentmeier, R. Geffers, E. Jost, R.A.F. MacLeod, S. Nagel,
S. Röhrs, M. Scherr, H.G. Drexler (DSMZ, Braunschweig, Germany)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Auditorium 2
CHRONIC MYELOID LEUKEMIA – BIOLOGY
Chairs: J Goldman (Hammersmith Hospital, London, United Kingdom)
P Rousselot (Hôpital André Mignot, Paris, France)
10:30 – 10:45
0880 DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/- INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST PHASE: 24-MONTH DATA FROM THE START PROGRAM
G. Saglio, H. Dombret, D. Rea, S. Corm, J. Cortes, D.W. Kim,
F.T. Garzon, P. Paliwal, M. Baccarani, G. Martinelli,
C. Gambacorti-Passerini (University of Torino, Orbassano-torino, Italy)
10:45 – 11:00
0930 IDENTIFICATION OF CANDIDATE GENES SUSTAINING BCR-ABL ONCOGENIC SIGNALLING AND CML PROGRESSION THROUGH A GENETIC TOOL BASED ON BCR-ABL TRANSGENIC DROSOPHILA MELANOGASTER
F. Messa, F. Arruga, E. Bracco, I. Iacobucci, C. Panuzzo, E. Messa,
A. Rotolo, T. Kalebic, M. Baccarani, F. Feiguin, R. Bernardoni,
G. Martinelli, G. Saglio, D. Cilloni (University of Turin, Turin, Italy)
11:00 – 11:15
0931 MULTIDRUG RESISTANCE GENE (MDR1) POLYMORPHISMS ARE ASSOCIATED WITH MAJOR MOLECULAR RESPONSE TO STANDARD-DOSE IMATINIB IN CHRONIC MYELOID LEUKEMIA
S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers,
M. Molimard, F.X. Mahon (Université INSERM, Bordeaux, France)
11:15 – 11:30
0932 IMATINIB RESPONSE PREDICTION IN EARLY AND LATE CHRONIC PHASE CML BY EXPRESSION PROFILING
S. Schmidt, D. Fong, D. Wolf, T. Lion, A. Petzer, G. Gastl (Medical
University Innsbruck, Innsbruck, Austria)
11:30 – 11:45
0934 DASATINIB LONG-TERM EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH RESISTANCE OR INTOLERANCE TO IMATINIB: A TWO-YEAR UPDATE OF THE START-C STUDY
F. Cervantes, M. Baccarani, J. Lipton, Y. Matloub, R. Sinha,
R.M. Stone, M. Mauro (Hospital Clinic I Provincial, Barcelona, Spain)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C1
EPIGENETICS, TRANSCRIPTION AND SIGNALING
Chairs: R Delwel (Erasmus Medical Center, Rotterdam, The Netherlands)
P Vyas (Weatherall Institute of Molecular Medicine, Oxford,
United Kingdom)
10:30 – 10:45
0935 CEBPA PROMOTER HYPERMETHYLATION IN IMMATURE ACUTE MYELOID/T-LYMPHOID LEUKEMIA IS ASSOCIATED WITH WIDESPREAD EPIGENETIC CHANGES
B.J. Wouters, M.E. Figueroa, Y. Li, A.W. Langerak, P.J.M. Valk,
B. Löwenberg, J.M. Greally, R. Delwel, A. Melnick (Erasmus University
Medical Center, Rotterdam, The Netherlands)
10:45 – 11:00
0936 LEUKEMIC TRANSFORMATION BY PLZF/RARA IS MEDIATED BY THE RECRUITMENT OF THE PRC1 POLYCOMB GROUP COMPLEX
E. Duprez, A. Boukarabila, J. Saurin, E. Batshé, N. Mosadegh, P. Otte,
J. Pradel, C. Muchardt, H. Sieweke, A. Duprez (Centre d'Immunologie
de Marseille, Marseille Cedex 09, France)
11:00 – 11:15
0937 SITE-SPECIFIC UBIQUITINATION OF THE G-CSF RECEPTOR AT EARLY ENDOSOMES DETERMINES ITS LYSOSOMAL SORTING AND SIGNAL DOWNREGULATION
A. Wolfler, M Irandoust, J Gits, O Roovers, I.P. Touw (Erasmus Medical
Center, Rotterdam, The Netherlands)
11:15 – 11:30
0938 THE ANTIOXIDANT PROTEIN PEROXIREDOXIN 4 DYNAMICALLY INTERACTS WITH THE CYTOPLASMIC DOMAIN OF G-CSF RECEPTOR IN EARLY ENDOSOMES AND ATTENUATES G-CSFINDUCED PROLIFERATION IN MYELOID PROGENITOR CELLS
K. Palande, O. Roovers, J. Gits, I.P. Touw (Erasmus Medical Centre,
Rotterdam, The Netherlands)
11:30 – 11:45
0939 SMALL MOLECULE XIAP INHIBITORS PRIME CHILDHOOD ACUTE LEUKEMIA CELLS FOR TRAIL-INDUCED APOPTOSIS AND OVERCOME BCL-2-MEDIATED RESISTANCE
S. Fulda, M. Fakler, S. Löder, M. Vogler, I. Jeremias, K.M. Debatin,
(University Children's Hospital, Ulm, Germany)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C2
ACUTE MYELOID LEUKEMIA – BIOLOGY II
Chairs: R Gale (University College London, London, United Kingdom)
F Lo Coco (University Tor Vergata, Rome, Italy)
10:30 – 10:45
0940 A KIT-INDEPENDENT ONCOGENIC PATHWAY IN NEOPLASTIC MAST CELLS THAT INVOLVES BTK AND IS DISRUPTED BY THE KIT/BTK-TARGETING DRUG DASATINIB
K.V. Gleixner, M. Mayerhofer, U. Rix, G. Hörmann, A. Gruze,
M.T. Krauth, W.F. Pickl, C. Sillaber, G. Superti-Furga, P. Valent
(Medical University of Vienna, Vienna, Austria)
10:45 – 11:00
0941 INSERTION OF FLT3 INTERNAL TANDEM DUPLICATION IN THE BETA-1-SHEET OF THE TYROSINE KINASE DOMAIN-1 IS ASSOCIATED WITH CHEMO-RESISTANCE AND INFERIOR CLINICAL OUTCOME
S. Kayser, R.F. Schlenk, F. Breitenbücher, M. Porebski, K. Wittke, J. Du,
S. Groner, D. Späth, J. Krauter, A. Ganser, H. Döhner, T. Fischer,
K. Döhner (University of Ulm, Ulm, Germany)
11:00 – 11:15
0942 AUTOCRINE IGF-1/IGF-1R SIGNALING IS RESPONSIBLE FOR PI3K/AKT CONSTITUTIVE ACTIVATION IN PRIMARY AML BLASTS
J. Tamburini, N. Chapuis, V. Bardet, L. Willems, S. Park, A. Green,
P. Cornillet-Lefebvre, P. Mayeux, C. Lacombe, D. Bouscary (Institut
Cochin, Paris, France)
11:15 – 11:30
0943 PROGNOSTIC IMPACT OF WT1 MUTATIONS IN THE CONTEXT OF OTHER MOLECULAR MARKERS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA (AML): A STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)
V.I. Gaidzik, S. Moschny, A. Becker, S. Groner, D. Spaeth, J. Krauter,
B. Schlegelberger, A. Ganser, H. Doehner, R.F. Schlenk, K. Doehner
(University Hospital of Ulm, Ulm, Germany)
11:30 – 11:45
0944 MOLECULAR ANALYSIS OF T(15-17) GENOMIC BREAKPOINTS IN SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA ARISING AFTER TREATMENT OF MULTIPLE SCLEROSIS
S.K. Hasan, A.N. Mays, T. Ottone, A. Ledda, G. La Nasa, C. Cattaneo,
E. Borlenghi, L. Melillo, E. Montefusco, J. Cervera, C. Stephen,
G. Satchi, A. Lennard, J.A. Byl, N. Osheroff, S. Amadori, C.A. Felix,
M.T. Voso, W.R. Sperr, J. Esteve, M.A. Sanz, D. Grimwade, F. Lo-Coco
(University Tor Vergata, Rome, Italy)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C3
PLATELETS AND THROMBOCYTOPENIA
Chairs: A Falanga (Ospedali Riuniti Bergamo, Bergamo, Italy)
H ten Cate (Maastricht University Medical Center, Maastricht, The Netherlands)
10:30 – 10:45
0945 EVALUATING THE LONG-TERM EFFICACY OF ROMIPLOSTIM (AMG 531) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DURING AN OPEN-LABEL EXTENSION STUDY
A. Newland, M.A. Sanz, E. Bourgeois, C. Grande, P.A.W. te Boekhorst,
E. Vellenga, Y. Shi, D. Berger, D.J. Kuter (The Royal London Hospital,
London, United Kingdom)
10:45 – 11:00
0946 SINGLE AND MULTIPLE ORAL DOSES OF LGD-4665, A SMALL MOLECULE THROMBOPOIETIN RECEPTOR AGONIST, INCREASE PLATELET COUNTS IN HEALTHY MALE SUBJECTS AND DEMONSTRATE POTENTIAL TO TREAT THROMBOCYTOPENIC PATIENTS
E. Dziewanowska, J. Zhang, P. Kapil, G. Greenberg, M. Matsumoto,
J. Schindler, J. Berg, B. Newberry (Ligand Pharmaceuticals, La Jolla,
California, USA)
11:00 – 11:15
0947 RECRUITMENT OF T-CELLS INTO BONE MARROW OF ITP PATIENTS POSSIBLY DUE TO ELEVATED EXPRESSION VLA-4 AND CX3CR1
B. Olsson, B. Ridell, L. Carlsson, S. Jacobsson, H. Wadenvik
(University of Gothenburg, Gothenburg, Sweden)
11:15 – 11:30
0948 CLINICAL-MOLECULAR PREDICTORS OF THROMBOCYTOPENIAAND RISK OF BLEEDING IN PATIENTS WITH VON WILLEBRANDDISEASE TYPE 2B: A PROSPECTIVE STUDY IN A COHORT OF 67PATIENTS
A.B. Federici, L. Baronciani, G. Castaman, P.M. Mannucci,
M.T. Canciani, P. Bucciarelli, A. Pecci, P.L. Lenting, P.G. De Groot
(University of Milan, Milan, Italy)
SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C4
STEM CELL BIOLOGY AND MICROENVIRONMENT
Chairs: D Bryder (Lund University, Lund, Sweden)
C Lacombe (Hôpital Cochin, Paris, France)
10:30 – 10:45
0950 MICRORNA-223 INHIBITS E2F1 DURING GRANULOPOEIS AND ISDOWNREGULATED IN AML
J.A. Pulikkan, V. Dengler, A. Peerzada, C. Müller Tidow, S. Buhlander,
D. Tenen, G. Behre (LZG AG BEHRE, Halle, Germany)
10:45 – 11:00
0951 EARLY ROLE OF THE NON-CANONICAL NF-KB PATHWAY ON THEMYELOID DIFFERENTIATION OF CD34+ HEMATOPOIETIC STEM/PROGENITOR CELLS
G. Andreotti De Molfetta (University of Sao Paulo, Ribeirao Preto – Sp,
Brazil)
11:00 - 11:15
0952 BONE MARROW STROMA CELLS REGULATE TIEG1 EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS - ROLE OF TGFBETA SUPERFAMILY MEMBERS AND TIEG1 IN CHEMOTHERAPY ESCAPE
E. Munthe, G. Døsen-Dahl, M.K. Nygren, H. Stubberud, E. Rian
(Rikshospitalet University Hospital, Oslo, Norway)
11:15 - 11:30
0953 EXPRESSION OF CEBPA DEFINES A DISTINCT CELL POPULATION WITHIN THE MURINE HEMATOPOIETIC STEM CELL AND MULTIPOTENT PROGENITOR COMPARTMENT
A. Wolfler, A.A. Danen-van Oorschot, M. Valkhof, P. van Strien,
E.J. Rombouts, I.P. Touw (Erasmus Medical Center, Rotterdam,
The Netherlands)
SIMULTANEOUS SESSIONS
10:30 - 11:45 Hall C5
NOVEL THERAPIES, DRUG RESISTANCE AND PHARMACOLOGY
Chairs: J Jurlander (Rigshospitalet, Copenhagen, Denmark)
P Kearns (The Institute of Child Health, Birmingham,
United Kingdom)
10:30 - 10:45
0954 MODULATING NOTCH1 WITH SIGNATURE-BASED SMALLMOLECULE LIBRARY SCREENING
G. Roti, K. Ross, C. Mecucci, J. Aster, K. Stegmaier (Dana Farber
Cancer Insitute, Boston, USA)
10:45 - 11:00
0955 SGI-1252: A POTENT SMALL MOLECULE JAK2 INHIBITOR
L. Warner, E. Gourley, X.H. Liu, C. Olsen, C. Parker, J. Prchal,
H. Vankayalapati, D. Bearss (SuperGen, Inc., Salt Lake City, USA)
11:00 - 11:15
0956 SELECTIVE JAK INHIBITION IS EFFICACIOUS AGAINST MULTIPLEMYELOMA CELLS AND REVERSES THE PROTECTIVE EFFECTSOF CYTOKINE AND STROMAL CELL SUPPORT
S. Fridman, J. Li, E. Caulder, M. Favata, D. Rodgers, P. Combs,
C. Newton, R. Redman, M. Friedman, K. Vaddi (Incyte Corporation,
Wilmington, USA)
11:15 - 11:30
0957 FOLATE GENE VARIANTS AFFECT METHOTREXATE-RELATEDTOXICITY IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
A.. Ongaro, M. Della Porta, C. Ambrosio, A. Caruso, F.F. Masieri, F. Di
Raimondo, D. Gemmati (Department of Morphology and Embryology,
University of Ferrara, Ferrara, Italy)
11:30 - 11:45
0958 OVEREXPRESSION OF THE IL3/IL5/GM-CSFRB AS POTENTIAL MECHANISM LEADING TO SURVIVAL FACTOR ACTIVATION INRESPONSE TO ABL-INHIBITOR TREATMENT
N. Härtel, T. Klag, A. Hochhaus, P. La Rosée (Medizinische Fakultät
Mannheim, Universität Heidelberg, Mannheim, Germany)
Print view ]
